Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.23.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Revenues $ 603,359 $ 568,704 $ 761,319
Cost of revenues 375,877 271,817 307,713
Amortization of intangible assets 428,431 428,431 428,434
Gross loss (profit) 200,949 131,544 (25,172)
Operating expenses:      
Research and development 705,646 783,665 926,697
Less - research and development grants (437,045) (315,967) (525,838)
Research and development, net 268,601 467,698 400,859
Sales and marketing 566,896 625,031 673,986
General and administrative 1,893,179 1,345,495 1,414,370
Goodwill impairment 265,089
Intangible asset impairment 2,108,117
Total operating expenses 4,836,793 2,438,224 2,754,304
Operating loss 5,037,742 2,569,768 2,729,132
Financial expenses (income), net (Note 14) (528,195) (50,904) 9,814,605
Net loss $ 4,509,547 $ 2,518,864 $ 12,543,737
Net loss per ordinary share:      
Basic net loss per ordinary share (in Dollars per share) $ 0.03 $ 0.06 $ 0.49
Weighted average number of ordinary shares used in computing basic net loss per ordinary share (in Shares) 129,144,562 44,453,153 25,581,000